obesity treatment
Insider Insights

Scotland leads the UK in approving Mounjaro for obesity treatment


Scotland has made a significant advancement in obesity treatment by becoming the first UK nation to approve the use of Eli Lilly’s Mounjaro (tirzepatide) under the NHS. This decision, announced by the Scottish Medicines Consortium (SMC), allows adults with a body mass index (BMI) of 30 kg/m² or more, along with at least one weight-related health condition, to access this innovative therapy.

Mounjaro, originally developed for diabetes management, has shown substantial efficacy in weight reduction, marking a crucial step in addressing obesity—a major public health challenge. The approval is particularly noteworthy as it sets a lower BMI threshold for eligibility compared to England, where the National Institute for Health and Care Excellence (NICE) has proposed a BMI threshold of 35 kg/m². This highlights regional differences in healthcare policies within the UK and underscores Scotland’s proactive approach to tackling obesity through advanced medical treatments.

The final guidance from NICE is anticipated in October 2024, following the closure of the public consultation period on 25th June 2024. The decision by the SMC reflects a broader commitment to enhancing patient access to effective obesity treatments, aligning with global trends in healthcare where weight management therapies are becoming increasingly prioritised due to their impact on overall health and related co-morbidities.

For healthcare professionals and stakeholders, this development emphasises the importance of staying informed about regional policy changes and their implications for patient care. It also illustrates the dynamic nature of market access in the pharmaceutical sector, where approvals and guidelines can vary significantly across different jurisdictions.

This move by Scotland sets a precedent and could potentially influence future decisions and policies regarding obesity treatment across the UK and beyond.


Pharmaforum. Scotland first UK nation to clear Mounjaro use for obesity. Accessed 12 June 2024.

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.